



Center for Medicare Services approves CIBMTR HCT study in Medicare patients with MDS as eligible for coverage with evidence development

“Assessment of Stem Cell Transplantation in Medicare Beneficiaries with Myelodysplastic Syndrome and Related Disorders – Part I” (10-CMSMDS-1)

Primary Aim

The primary aim of this study is to prospectively examine outcomes of allogeneic HCT in adults ≥ 65 years of age with MDS to determine whether their outcomes are similar to those in younger patients.

Opening: December 15, 2010

Detailed protocol and related materials available at:
<http://www.cibmtr.org/HCTforMDS>

Participants in this study will be eligible for claims coverage from CMS under the “coverage with evidence development (CED)” mechanism. (<http://cms.gov>)

Patient Eligibility

- Diagnosis of MDS related disorders, including CMML and therapy-related MDS.
- Age ≥ 65 or age < 65 and Medicare beneficiary.
- Willingness to participate and sign informed consent for NMDP/CIBMTR’s “*Protocol for a Research Database for Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries.*”

Transplant Center Participation Requirements

- Submission of the study subject registration form via fax or email.
- Completion of Form 2400 (Pre-Ted) with:
 - The RCI-BMT box checked, and the Study ID# entered as **“10-CMSMDS-1”**
 - Consent for Research marked as “Yes”
- Submission of Comprehensive Report Forms to CIBMTR for all registered study patients.

For questions, please contact:

Anne Dircks, CCRP
 Sr. Clinical Research Specialist, CIBMTR-Mpls
adircks@nmdp.org 612.884.8209